Bioclinica, a specialty clinical trials technology and services provider, has introduced OnPoint Direct, a Clinical Trial Management System (CTMS) geared toward mid-market biopharma and CROs. OnPoint Direct offers a cost-friendly pricing structure that empowers organizations to adopt a full-featured clinical trial management solution without the complex configuration, capital investment or perpetual licensing models customary of other systems.

“We recognize that some organizations run fewer studies, so we created a purpose-built CTMS just for them,” said Bioclinica’s vice president of Product Management, eHealth Solutions, Ron Burns. OnPoint Direct is a SaaS-based rapid start version of Bioclinica’s OnPoint CTMS, which is used by large pharma companies and CROs around the globe to manage their clinical trials. “Bioclinica now provides organizations with a premier end-to-end study management tool that takes them from rapid study startup to study conduct, and on through to study close-out with efficiencies built into every step of the process,” Burns said.

OnPoint Direct is an out-of-the-box solution that shares all of the same core functionality as the original OnPoint, but with streamlined configuration, slashing ramp-up time and investment. The SaaS-based offering is delivered through Bioclinica’s secure eHealth Cloud, which leverages the Bioclinica Cloud Transformation Gateway, a secure standards-based integration exchange that connects its eClinical Platform to innovative third-party applications and industry data banks.

“Organizations can now get studies up and running in a matter of weeks compared to several months,” Burns said. “With OnPoint Direct we focused on workflows people are using every day, like those related to Microsoft Word, Excel, Outlook and SharePoint. OnPoint Direct seamlessly integrates with this suite, creating a familiar and comfortable working environment.” The approach reduces training time and speeds adoption.